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Abstract
Selenium (Se) is an essential trace element in human nutrition, but its role in certain health conditions, particularly among Se
sufficient populations, is controversial. A genome-wide association study (GWAS) of blood Se concentrations previously
identified a locus at 5q14 near BHMT. We performed a GW meta-analysis of toenail Se concentrations, which reflect a longer
duration of exposure than blood Se concentrations, including 4162 European descendants from four US cohorts. Toenail Sewas
measured using neutron activation analysis. We identified a GW-significant locus at 5q14 (P < 1 × 10−16), the same locus
identified in the published GWAS of blood Se based on independent cohorts. The lead single-nucleotide polymorphism (SNP)
explained ∼1% of the variance in toenail Se concentrations. Using GW-summary statistics from both toenail and blood Se, we
observed statistical evidence of polygenic overlap (P < 0.001) and meta-analysis of results from studies of either trait (n = 9639)
yielded a second GW-significant locus at 21q22.3, harboring CBS (P < 4 × 10−8). Proteins encoded by genes at 5q14 and 21q22.3
function in homocysteine (Hcy) metabolism, and index SNPs for each have previously been associated with betaine and Hcy
levels in GWAS. Our findings show evidence of a genetic link between Se and Hcy pathways, both involved in cardiometabolic
disease.
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Selenium (Se) is an essential trace element in human nutrition;
its deficiency has been associated with a variety of health disor-
ders and has been the subject of intensive investigation (1,2).
However, the potential benefits of Se’s anticancer effects have re-
cently been tempered by its potential adverse cardiometabolic
effects, necessitating furthermechanistic selenoprotein research
as well as studies on dietary or supplemental Se intake for opti-
mal health (1,3–5).
Biomarkers of Se exposure such as blood and nail Se concen-
trations vary substantially and are influenced by diet, geograph-
ical region, supplements and smoking status (2). Characterizing
genetic variation in response to Se exposure may be especially
useful in identifying individuals most susceptible to the adverse
effects of Se, whomight be advised to avoid Se supplementation.
A recent genome-wide association study (GWAS) of blood Se con-
centrations (6) reported a GW-significant locus at 5q14, harboring
BHMT, BHMT2 and DMGDH (6). Although blood and toenail Se
concentrations are validated biomarkers of Se exposure, the lat-
termay reflect a longer average duration of exposure and perhaps
a more stable trait amendable to GWAS (7,8). We thus aimed to
perform the first GWAS of toenail Se concentrations and to com-
pare our findings with those reported for blood Se, enabling in-
sight to the genetic architecture underlying similar traits which
purportedly capture different measures of exposure duration.
Results
We conducted a GW meta-analysis of toenail Se concentration
using data from a total of 4162 men and women sourced from
four independent population-based studies: Coronary Artery
Risk Development in Young Adults (CARDIA), Johnston County
Osteoarthritis Project (JoCo), Nurses’ Health Study (NHS) and
the Health Professionals Follow-up Study (HPFS) (Supplementary
Material, Table S1 and Fig. S1). We observed little evidence for
genomic inflation (λ = 1.02, Supplementary Material, Fig. S2). Sev-
eral single-nucleotide polymorphisms (SNPs) in low LD (CEU: r2 >
0.30) reached GW-significance (P < 5 × 10−8) and mapped to
5q14.1; the same locus reported by Evans et al. (6) in a GWAS of
blood Se (Table 1). Our lead SNP (rs17823744) explained ∼1% of
the variance in toenail Se concentrations in the NHS and HPFS.
None of our nominally significant loci for toenail Se were asso-
ciated with blood Se.
In gene-based analysis of Se metabolism and selenoprotein
candidate genes, only thioredoxin reductase 1 (TXNRD1) was
significantly associated with toenail Se levels (Table 2, gene-
level P < 7 × 10−3). The top SNP for this gene also met sub-GW sig-
nificance (Table 1). No candidate genes in these pathways were
significantly associated with blood Se levels.
GW associations of toenail Se were significantly enriched for
genes involved in DARPP32 events (Reactome), the β-catenin
phosphorylation cascade (Reactome), G1 phase cell cycle regula-
tion (Reactome), PP2A-mediated dephosphorylation (Reactome)
and the ERK inactivation pathway (Reactome; FDR < 0.05). GWas-
sociations of blood Se did not yield significant enrichment for
specific biological pathways.
We observed no significant overlap of associated effects in the
two data sets when applying a genome-wide test for pleiotropy
(P = 0.86). However, in tests for genetic overlap between GW sig-
nificant (P1 ≤ 5 × 10−8), suggestive (P1 ≤ 1 × 10−5) and nominal
(P1 ≤ 0.05) blood Se SNPs (data set1) and toenail Se SNPs (data






Toenail Se (n = 4162) Evans et al. blood Se
(n = 5477)
Closest gene(s)b, eQTLd
EAF βc ± SE P-value I2 Effect P-value I2
1 82 993 022 rs17498581 T/C 0.10 0.024 ± 0.006 9.34 × 10−6 42 + 0.99 28 LPHN2, TTLL7
1 241 584 774 rs2802728 T/C 0.90 0.026 ± 0.006 6.28 × 10−6 0 – 0.09 0 SDCCAG8
2 143 476 161 rs352889 A/G 0.39 0.016 ± 0.004 4.16 × 10−6 22 + 0.74 0 KYNU, ARHGAP15
5 28 41 906 rs7702905 A/G 0.28 −0.017 ± 0.004 8.09 × 10−6 33 + 0.56 0 IRX2, C5orf38
5 78 372 981 rs248381 A/G 0.50 −0.025 ± 0.003 3.01 × 10−13 26 – 1.07 × 10−25 0 DMGDH, ARSB, BHMT2
5 78 380 732 rs17823744 A/G 0.88 −0.045 ± 0.005 9.91 × 10−17 0 – 1.62 × 10−21 0 DMGDH, ARSB, BHMT2
5 78 447 080 rs7700970 T/C 0.30 0.030 ± 0.004 2.21 × 10−11 26 + 2.88 × 10−18 71 BHMT, BHMT2, JMY
5 78 452 172 rs567754 T/C 0.33 −0.018 ± 0.004 4.80 × 10−6 41 – 3.22 × 10−16 26 BHMT, BHMT2, JMY↑
5 78 780 798 rs6859667 T/C 0.96 −0.045 ± 0.008 1.24 × 10−7 19 – 3.75 × 10−6 0 HOMER1, JMY
5 79 178 950 rs10079417 T/C 0.23 0.018 ± 0.004 6.10 × 10−6 18 + 0.30 0 CMYA5,
5 133 474 474 rs756699 T/C 0.86 0.022 ± 0.005 9.61 × 10−6 0 + 0.78 31 VDAC1, TCF7↑
8 21 01 183 rs17685410 A/G 0.30 0.018 ± 0.004 1.60 × 10−6 38 + 0.06 0 MYOM2↓, CSMD1, KBTBD11↓,
ARHGEF10↓
11 102 715 194 rs313426 A/G 0.31 −0.018 ± 0.004 2.24 × 10−6 0 + 0.23 0 DYNC2H1, DCUN1D5, PDGFD
12 52 561 533 rs1596370 A/G 0.21 −0.021 ± 0.004 8.34 × 10−7 0 – 0.21 11 CALCOCO1, HOXC13
12 103 169 535 rs7975161 T/C 0.16 −0.023 ± 0.005 1.18 × 10−6 0 + 0.84 0 TXNRD1↑, NFYB
18 21 225 855 rs6508367 T/C 0.96 −0.040 ± 0.009 7.50 × 10−6 23 – 0.28 0 ZNF521, SS18
19 19 690 101 rs2163813 T/G 0.74 −0.018 ± 0.004 4.56 × 10−6 58 – 0.42 0 ZNF14, ZNF101, ATP13A1↑
EA, effect allele; NEA, non-effect allele; EAF, effect allele frequency; eQTL, expression quantitative trait loci.
aShown are top SNPs (P < 5 × 10−6) associated with toenail Se concentrations pruned for linkage disequilibrium (r2 < 0.3). P-values in bold face achieve genome-wide
significance (P < 5 × 10−8).
bGenic SNPs and their corresponding genes are in bold face.
cEffect sizes represent change in natural logarithm transformed toenail Se µg/g per effect allele. Only direction of effect is presented for blood Se since Evans et al. modeled
residuals of a linear regression, thus limiting interpretation and comparison with effect sizes presented for toenail Se.
dExpression QTLs for index SNP or perfect proxy (CEU: r2 = 1) derived from blood (9) are underlined. Arrows indicate increased and decreased expression, respectively,
relative to effect allele.
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set2) with P2 ≤ 0.05, the number of SNPs associated in both data
sets was significantly more than expected (P < 6.7 × 10−6 for GW
significant, suggestive and nominal data set1 SNPs). Moreover,
we observed a significant concordance of genetic risk (i.e. direc-
tion of effects) between the two data sets (P < 0.001).
Given evidence of polygenic overlap across phenotypes, we
conducted a sample size weightedmeta-analysis across all stud-
ies of toenail and blood Se and identified a secondGW-significant
locus at 21q22.3; harboring CBS (P < 4 × 10−8, Table 3, Supplemen-
tary Material, Figs S3 and S4); and enrichment for genes involved
in the biological process of hearing (Panther, FDR < 0.03). The lat-
ter is related to Gene Ontology’s biological process: Sensory
Perception of Sound (GO:0007605); which was not a significant
pathway (FDR = 0.79). CBS is plausibly linked to DMGDH-BHMT-
BHMT2 but is also a confirmed locus for homocysteine (Hcy) sta-
tus (10,11). To gain insight to potential confounding or pleiotropy,
we examined whether any of our other top Se loci were asso-
ciated with Hcy status in the Women’s Genome Health Study
(11). With the exception of CBS, none of our top Se loci (Tables 1
and 3) was associated with Hcy levels after the Bonferonni
correction (P ≥ 0.02). We also conducted the complementary ex-
periment: we tested whether any additional Hcy loci were asso-
ciated with Se. After the Bonferonni correction, the variant in
CPS1 associated with higher Hcy levels (rs742239, A) was signifi-
cantly associated with higher Se in the combined analysis of
toenail (P = 0.16) and blood (P = 0.0004) Se levels (combined
P = 0.0003). Besides gene-based associations between CBS and
toenail (P = 0.001) and blood Se (P = 0.0008), only nominally signifi-
cant associations were observed for other candidates of the me-
thionine (Met) metabolism and trans-sulfuration (TS) pathways:
DNMT1 (P = 0.02 for toenail Se), CSAD (P = 0.04 for toenail Se) and
MAT2B (P = 0.049 for blood Se).
Discussion
Se is an essential mineral, but its role in certain health condi-
tions, particularly among Se sufficient populations, is controver-
sial warranting further research on dietary or supplemental Se
intake for optimal health. Information on modifiable and com-
mon genetic factors impacting exposure to Se may advance this
Table 2. Associations between Se function and metabolism candidate genes and Se concentrationsa
Chr Gene Toenail Se Blood Se
Gene level P-value Best SNP Best SNP P-value Gene level P-value Best SNP Best SNP P–value
1 DIO1 0.04 rs2272928 5.76 × 10−3 0.41 rs4926616 0.11
1 SEP15 0.22 rs1407131 0.05 0.17 rs7537393 0.014
3 GPX1 0.15 rs3811699 0.06 0.05 rs1865741 0.02
5 SEPP1 6.99 × 10−3 rs2329999 1.30 × 10−3 0.37 rs230814 0.10
5 GPX3 0.04 rs3805433 3.96 × 10−3 0.01 rs12517537 6.68 × 10−4
12 TXNRD1 1.00 × 10−5 rs7975161 1.18 × 10−6 0.08 rs17035401 0.02
14 GPX2 0.31 rs12147448 0.12 0.21 rs7160073 0.03
14 DIO2 0.18 rs2267872 0.05 0.12 rs224995 0.03
14 DIO3 0.17 rs2895917 0.02 0.34 rs2895917 0.10
15 SELS 0.39 rs6598440 0.035 0.58 rs2277593 0.14
19 GPX4 0.65 rs757232 0.14 0.46 rs2074445 0.10
22 TXNRD2 0.84 rs13057441 0.11 0.29 rs2238786 0.05
aShown are results for candidate genes achieving at least nominal significance (P ≤ 0.05) in gene-based testing. P-values in bold face are those achieving gene-level
significance (P < 0.0008).
Table 3. Top loci from GW meta-analysis of toenail and blood Se concentrationsa
Chr Position (Hg18) Index SNP EA/NEA EAF n Z-scoreb P-value I2 Closest gene(s)c, eQTLd
5 78 313 985 rs672413 A/G 0.32 9639 7.53 5.21E−14 0 ARSB↓, LHFPL2, DMGDH
5 78 327 716 rs705415 T/C 0.14 8054 −6.23 4.64E−10 52 DMGDH, ARSB
5 78 336 153 rs3797535 T/C 0.08 9639 7.94 2.05E−15 0 DMGDH, ARSB, BHMT2
5 78 340 070 rs11951068 A/G 0.07 9639 6.72 1.86E−11 0 DMGDH, ARSB, BHMT2
5 78 352 232 rs921943 T/C 0.29 9639 13.14 1.90E−39 39 DMGDH, ARSB, BHMT2
5 78 421 601 rs10944 T/G 0.49 9639 12.65 1.13E−36 44 BHMT2, BHMT
5 78 452 172 rs567754 T/C 0.34 9639 −9.11 8.38E−20 49 BHMT, BHMT2, JMY
5 78 460 944 rs558133 A/C 0.69 9639 −6.55 5.60E−11 0 BHMT, BHMT2, JMY
5 78 780 798 rs6859667 T/C 0.96 9639 −6.92 4.40E−12 9 HOMER1, JMY
21 43 351 566 rs6586282 T/C 0.17 9639 −5.89 3.96E−09 15 CBS, PKNOX1↓, U2AF1, STAG3OS↓
21 43 356 005 rs1789953 T/C 0.14 9639 5.52 3.40E−08 0 CBS↓, PKNOX1, U2AF1, WDR4↑
21 43 360 033 rs234709 T/C 0.45 9639 −5.84 5.23E−09 0 CBS↓, PKNOX1, U2AF1
EA, effect allele; NEA, non-effect allele; EAF, effect allele frequency; eQTL, expression quantitative trait loci.
aShown are genome-wide significant SNPs (P < 5 × 10−8) associated with Se concentrations pruned for linkage disequilibrium (r2 < 0.3).
bEffect sizes represent change in Z-score per effect allele.
cGenic SNPs and their corresponding genes are in bold face.
dExpression QTLs for index SNP or perfect proxy (CEU: r2 = 1) derived from blood (9) are underlined. Arrows indicate increased and decreased expression, respectively,
relative to effect allele.
Human Molecular Genetics, 2015, Vol. 24, No. 5 | 1471
research. The current GWAS of toenail Se concentrations con-
firms an association with the 5q14 locus previously reported in
a recent GWAS of blood Se concentration (6), but combining re-
sults for toenail and blood Se concentrations, we reveal a second
locusmapping to 21q22.3. Our findings demonstrate genetic links
between long-term Se exposure and theHcymetabolic pathways.
Se exists in the diet in the form of selenomethionine (SeMet),
selenocysteine (Sec), selenate or selenite. Hydrogen selenide
(H2Se), a vital metabolite for selenoprotein synthesis and Se ex-
cretion, is generated from Sec by selenocysteine β-lyase or from
dietary selenite via its reductionwith glutathione (3,12). Approxi-
mately 53 and 39% of Se present in plasma and serum is in the
form of Sec residues in selenoprotein P (SePP) and glutathione
peroxidase 3 (GPx3), respectively, while the remaining Se is incor-
porated non-specifically in albumin and other proteins as SeMet
(13,14). Because SePP and GPx3 are fully expressed in Se adequate
individuals, variation in plasma Se levels is almost exclusively
limited to variation in the non-specific component (14). Serum
and plasma Se measures are sensitive to recent Se exposure
(14,15), which may partly explain the null findings of a recent
GWAS of serum Se (16). Blood presumably reflects Se exposure
over ∼120 days, corresponding to the lifespan of its erythrocyte
content, while toenail Se reflects exposure over a period of 26–
52 weeks (15). The GWAS of blood Se conducted by Evans et al.
(6) as well as the current GWAS of toenail Se both report signifi-
cant SNPs mapping to an intronic region of DMGDH. A second
SNP (rs7700970) in this region and in low LD (CEU: r2 = 0.22) to
our index SNP in DMGDH (rs17823744) also reached GW signifi-
cance and mapped to BHMT. In conditional analysis, Evans et al.
confirmed an independent effect of a second SNP in BHMT
(rs506500), which was also nominally significant in our GWAS
of toenail Se (P = 7.59 × 10−5). Leveraging the evidence of shared
genetics across these two measures of Se exposure, we revealed
a second GW-significant locusmapping to CBS, which Evans et al.
(6) initially described as highly suggestive. Whether these loci re-
flect variation in SeMet, Sec or another minor Se constituent is
unclear. Nevertheless, our finding suggests that blood and
toenails are stable measures of Se exposure amenable to GWAS
and share a similar genetic architecture, further corroborating
the utility of these biomarkers in traditional epidemiological
studies of Se exposure.
Proteins encoded by DMGDH, BHMT, BHMT2 and CBS all func-
tion in Hcy metabolism, which is composed of two intersecting
pathways, the Metmetabolism and TS pathways (Box 1) (17). Per-
turbations of these pathways are usually discussed with refer-
ence to their impact on Hcy levels and modification by vitamin
B status. Polymorphisms in CBS associated with higher Se levels
have previously been associated with higher Hcy levels in GWAS
(10,11). The latter suggests these variants likely reduce CBS activ-
ity, since CBS is the regulatory enzyme in the TS pathway, which
is the only known activity for Hcy elimination (19). An impaired
TS pathway resulting in elevated Hcy levels may alter the Met
cycle and production of S-adenosylmethionine (SAM), a primary
methyl donor for numerous methylation reactions, including
those required for Se excretion (Fig. 1) (12,20,21). Alternatively,
the role of glutathione in metabolism of selenite may contribute
to variation in Se levelswhen TS is altered (22). Finally, SeMet and
its metabolites are reportedly substrates for all steps of the TS
pathway in vitro (23), but the in vivo importance of this pathway
to SeMet utilization remains to be demonstrated (24).
Among GW-significant SNPs mapping to BHMT-BHMT2-
DMGDH, variants linked with higher blood/toenail Se have been
previously associated with higher liver betaine-homocysteine
methyltransferase (BHMT) enzyme activity and protein level
(25) and lower plasma betaine levels (26,27). Unlike BHMT,
BHMT-2 cannot use betaine (28), thus we hypothesize that the
causal gene in this region is BHMT. Given three fungible sources
of methyl groups (Fig. 1), it is unlikely that variants in BHMT
alter Se levels through a mechanism downstream of Met gener-
ation but rather through a mechanism specific to BHMT. Se can
react with cysteine-rich regions present within the catalytic do-
main of enzymes such as protein kinase C where it may form se-
lenenyl-sulfide bonds with cysteines resulting in lower enzyme
activities (29). As BHMT is a zinc-dependent cysteine-rich en-
zyme, an altered thiol redox status could influence its activity
in much the same way as for protein kinase C (30). How this po-
tential interaction between Se and BHMT might impact utiliza-
tion or accumulation of Se is unclear.
Strengths of the current study include the use of four inde-
pendent population studies with toenail Se measured in the
same laboratory by the same technique, allowing for a sufficient-
ly sized sample with relatively uniform measures of Se for
analysis. However, a few limitations of the study warrant consid-
eration. Corresponding Hcy measures were available for too few
of the participants and thus did not allow us to explore in detail
potential pathways shared by Hcy and Se. Within Se-sufficient
populations, such as those of the current study, whether higher
Se levels associated with variation at 5q14 or 21q22.3 predispose
to favorable or unfavorable (i.e. toxic) effects remains an open
question. Although blood and toenail Se concentrations are ac-
cepted markers of human Se status, Se concentrations them-
selves do not reflect its functional significance (31). Rather, the
nutritional functions of Se are achieved by SePP, GPx3 and 23
other selenoproteins (31). In gene-based analysis, toenail Se le-
vels were significantly associated with TXNRD1 and nominally
significant with selenoprotein P, plasma, 1 (SEPP1). None of the
candidate genes was significantly associated with blood Se le-
vels. While our associations with TXNRD1 and SEPP1 await con-
firmation, our most significant associations at 5q14 and 21q22.3
for both toenail and blood Se concentrations suggest markers of
long-term Se exposure aremore strongly influenced by pathways
Box 1. Normal plasma Hcy concentrations are main-
tained by converting Hcy to cysteine by action of the
enzyme cystathionine β synthase (CBS) or bymethylat-
ing Hcy to form methionine in reactions that can be
accomplished byone of three separate enzymatic path-
ways: (i) methionine synthase (MS) methylates Hcy by
using 5-methyltetrahydrofolate (5-MeTHF) as the me-
thyl donor and vitamin B-12 as a cofactor; (ii) betaine
homocysteine S-methyltransferase (BHMT) methy-
lates Hcy by using betaine as the methyl donor; and
(3) BHMT2 methylates Hcy by using S-methylmethio-
nine (SMM) as the methyl donor (Fig. 1). Dimethygly-
cine dehydrogenase (DMGDH) catalyzes the oxidative
demethylation of dimethylglycine, the product of
BHMT-mediated methylation, to form sarcosine. The
methionine formed from Hcy serves as the precursor
of S-adenosylmethionine (SAM), the primary methyl
donor for numerous methylations. When it donates
its methyl group, SAM is converted to S-adenosylho-
mocysteine (SAH), and SAH can be recycled to Hcy
(17,18). As shown in Figure 1 and further discussed in
the text, perturbations of these pathways may impact
selenium (Se) elimination and utilization.
1472 | Human Molecular Genetics, 2015, Vol. 24, No. 5
independent of those related to themineral’s biological function.
Clearer interpretation of our findings may require follow-up in
populations with a wider distribution of Se exposure.
Our findings are important in the context of increasing inter-
est in the relationship between Se and Hcy status as well as the
roles each potentially plays in cardiometabolic disease. Elevated
Hcy levels have consistently been associated with cardiovascular
disease risk in addition to other clinical conditions (32). Associa-
tions betweenmeasures of Se exposure and cardiometabolic out-
comes are contradictory (1,2). Cross-section epidemiological
studies report inverse relationships between serum Se levels
and Hcy (33), which contrasts with the positive relationship ob-
served in animals studies (30,34,35). Human Se supplementation
trials observed no effect of Se on Hcy levels (36,37). The discrep-
ancy in results between the human and animal studies may be
due to the extreme level of Se deficiency attained in the animal
studies, type of Se administered in experiments or cross-species
differences in relative importance of each pathway (30,34,38,39).
Regarding the latter, we note that unlike genetic variation in the
folate-dependent pathway, BHMT variation does not appear to
impact Hcy levels (10,11,40–42) and together suggests a less dom-
inant role of the BHMT/2 remethylation pathway in human Hcy
balance, a theory which contrasts that proposed for mice (39).
Nevertheless, our genetic findings suggest the interconnection
between Hcy, B vitamins, choline, betaine and Met might extend
to include Se.
In summary, we confirm two loci associated with long-term
measures of Se exposure. Both encode proteins involved in the
Met and TS pathways surrounding Hcy metabolism. Future mo-
lecular studies of these pathways or health outcomes implicated
by these pathwaysmight consider Se in addition to the tradition-
al set of co-factors. Likewise, future studies of dietary or
supplemental Se might account for genetic variation in Se




Coronary Artery Risk Development in Young Adults (CARDIA)
The CARDIA study is a prospective multicenter study with 5115
adults Caucasian and African-American participants of the age
group 18–30 years, recruited from four centers. The recruitment
was done from the total community in Birmingham, AL, from se-
lected census tracts in Chicago, IL, and Minneapolis, MN; and
from the Kaiser Permanente health plan membership in Oak-
land, CA. Details of the CARDIA study design have been previous-
ly published (43). Eight examinations have been completed since
initiation of the study in 1985–1986, respectively, in the years 0, 2,
5, 7, 10, 15, 20 and 25. Written informed consent was obtained
from participants at each examination and all study protocols
were approved by the institutional review boards of the partici-
pating institutions.
Johnston County Osteoarthritis Project (JoCo)
Begun in 1990, JoCo is an ongoing, population-based, prospective
cohort in Johnston County, NC, with follow-up examinations ap-
proximately every 5–7 years. Participants were enrolled following
household enumeration and represented civilian, non-institutio-
nalized African-Americans and Caucasians ≥45 years who were
residents of one of six townships in Johnston County for at
least 1 year and who were physically and mentally capable of
completing the study protocols. Although this was a study
Figure 1. Hcy metabolism.
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initially designed to assess osteoarthritis, therewas no pre-selec-
tion based on specific diseases, and data about multiple medical
conditions have been collected at each time point. At baseline
and each follow-up, participants completed two in-home or clin-
ic interviews and a clinical examination. Venipuncture for DNA
collectionwas instituted at the first follow-up (1999–2003) and co-
hort enrichment (2003–2004). Details of the study’smethodshave
been previously reported (44).
Nurses’ Health Study (NHS)
The NHS was established in 1976 when 121 700 female registered
nurses aged 30–55 years and residing in 11 large US states com-
pleted a mailed questionnaire on medical history and lifestyle
characteristics (45). Every 2 years, follow-up questionnaires
have been sent to update information on exposures andnewly di-
agnosed diseases and every 2–4 years, diet is assessed using a va-
lidated semi-quantitative FFQ. Blood was collected from 32 826
NHS members between 1989 and 1990. Women contributing to
the current analysis were those previously selected for one of
four independent GWAS in nested case–control studies of the
NHS cohort, initially designed for outcomes of type 2 diabetes
(T2D) (46), coronary heart disease (CHD) (47) and breast cancer
(BrCa) (48). Details pertaining to study design have been reported
elsewhere (46–48).
Health Professionals Follow-up Study (HPFS)
The HPFS was initiated in 1986 when 51 529 male health profes-
sionals between 40 and 75 years of age and residing in the USA
completed an FFQ and a questionnaire on lifestyle and medical
history. The participants have been followedwith repeated ques-
tionnaires on lifestyle and health every 2 years and FFQs every 4
years. Between 1993 and 1996, a blood sample was requested
from all active participants in the HPFS and collected from
18 225 men (49). Men contributing to the current analysis were
those previously selected for one of two nested case–control
studies of the HPFS cohort, initially designed for outcomes of
T2D (46) and CHD (47), as previously described (46,47).
This study was conducted according to the principles ex-
pressed in theDeclaration of Helsinki. All participants in the con-
tributing studies gave written informed consent including
consent for genetic analyses. Local institutional review boards
approved study protocols. The JoCo protocol was additionally ap-
proved by the review board at the Centers for Disease Control and
Prevention.
Assessment of toenail Se concentrations
Detailed procedures for toenail collections and processing in
each cohort have been reported previously (50–52). Toenail
clippings from all 10 toes were provided by NHS and HPFS parti-
cipants in 1982–1983 and 1986–1987, respectively. Toenail collec-
tions for CARDIA took place in 1986. and Toenail clippings from
all 10 toes were provided by NHS, HPFS and CARDIA participants
in 1982–1983, 1986–1987 and 1987, respectively(50). Toenail col-
lection for JoCo was instituted during the first and second fol-
low-up evaluations. Toenail Se concentrations were measured
using neutron activation analysis at the University of Missouri
Research Reactor between 2009 and 2011 for NHS and HPFS,
2006 and 2009 for CARDIA and 2004–2005 for JoCo. Details of ana-
lytical methods and information regarding validation of these
measures have previously been reported (15,53,54). Samples
of nail clippings from all toes were combined, providing a time-
integrated measure of exposure over approximately the prior
year owing to the elimination half-life of toenail Se, the growth
rate of toenails and the differential length of time (distance)
from cuticle synthesis to toenail clipping comparing the smallest
with largest toes. Potential laboratory drift was controlled by both
standard comparison procedures for neutron activation analysis
and repeated analysis of representative sample subsets. Intra-
assay coefficients of variation for Se were 2.45% for CARDIA, 3%
for JoCo and 2.4% for NHS and HPFS. We excluded individuals
with toenail Se concentrations >2.0 μg/g, which could reflect ex-
ogenous contamination or considerable excess ingestion of Se
supplements (15,53,54).
Genotyping, quality control and imputation
DNA was extracted from blood samples using conventional
methods. Genotyping was completed using the Affymetrix
Genome-Wide Human (Affy) 6.0 array (NHS-T2D, HPFS-T2D,
NHS-CHD, HPFS-CHD, CARDIA), Illumina Human-Hap550 array
(NHS-BrCa) or Illumina 1MDuo array (JoCo). Details of genotyping
process and quality control (QC) for each study population have
been described previously (46–48,55,56). In the CARDIA study,
genotyping was completed for 1720 individuals of European an-
cestry with a sample call rate ≥98%. Of these, 1585 had Se data
and were included in these analyses. A total of 578 568 SNPs
passed QC (MAF ≥ 2%, call rate ≥ 95%, HWE ≥ 10–4) and were
used for imputation. At a minimum, DNA samples that did not
meet a 90% completion threshold, and SNPs with low call rates
(<95%), were dropped. EIGENSTRAT (57) was used to carry-out an-
cestry analyses and any putative non-European samples (either
the HapMap YRI or CHB + JPT samples) were excluded for subse-
quent analyses. EIGENSTRAT was also used to generate inform-
ative principal components for population substructure.
Each study used MACH (58) or BEAGLE (59) to impute up to∼
2.5 million autosomal SNPs with NCBI build 36 of Phase II Hap-
Map CEU data (release 22) as the reference panel. Genotypes
were imputed for SNPs not present in/on arrays or for those
where genotyping had failed to meet the QC criteria. Imputation
results are summarized as an ‘allele dosage’ (a fractional value
between 0 and 2), defined as the expected number of copies of
the minor allele at that SNP.
Genome-widemeta-analysis of toenail Se concentrations
Each study used ProbABEL (60) or PLINK (61) to perform GWA-
testing for natural log-transformed Se concentrations across
∼2.5 million SNPs, based on linear regression under an additive
genetic model. Analyses were stratified by gender and adjusted
for age, smoking status [never/former, current (<15 cig/day), cur-
rent (≥15 cig/day)], geographical area of residence (NHS, HPFS,
JoCo) or study site (CARDIA) and top eigenvectors (number varies
by data set). Prior to meta-analysis, we removed SNPs with a
minor allele frequency <0.02 or low imputation quality scores, de-
fined as BEAGLE’s allelic r2 or MACH’s r2 < 0.30.
Meta‐analysis was conducted using a fixed effects model and
inverse‐variance weighting as implemented in METAL (see URLs
in Supplementary Material). The software also calculates the
genomic control parameter and adjusts each study’s standard er-
rors. Heterogeneity across studies was investigated using the I2
statistic and Q-test (62). The genomic inflation factor λ for each
study as well as the meta-analysis was estimated from the me-
dian χ2 statistic. SNP–Se associations (n = 2 378 986) based on re-
sults from at least 50% of the maximum sample size were used
to generate Manhattan, quantile–quantile and regional associ-
ation plots and for post hoc analysis (see below). SNPs imputed
by all studies (n = 1 167 113) were excluded from further
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presentation or discussion. The latter QC step did not remove po-
tentially novel loci but rather only SNPs in LDwith those reported
in Tables 1 and 3 and as shown in Supplementary Material, Fig-
ures S1 and S3. We considered P-values of <5 × 10−8 to indicate
GW significance (63).
Previously published GWAS of blood Se by Evans et al. (6)
We compared our results with the publically available summary
statistics of a previously reported GWAS of blood Se (6). Briefly,
participants were recruited in Australia from twins and their
families (n = 2603) and in the UK frompregnantwomen (n = 2874).
Erythrocyte Se (Australian samples) or whole blood Se (UK sam-
ples) were measured using inductively coupled plasma mass
spectrometry. Genotyping was performed with Illumina chips
and >2.5 million SNPs were imputed from HapMap data. Sum-
mary level data were provided from each contributing study.
We filtered and re-meta-analyzed the study-level results as de-
scribed above for the GWAS of toenails; which was similar to
the approach taken in the original analyses (6).
Candidate gene-based, pathway and pleiotropy analyses
We examined all SNPs in 59 genes spanning Se function, Se me-
tabolism, Met and TS pathways for associations with toenail and
blood Se concentrations using VEGAS (64). We used Meta-Ana-
lysis Gene-set Enrichment of variaNT Associations (MAGENTA,
version 2.4) (65) to test whether GW meta-analysis results for
toenail and blood Se were enriched for members of specific bio-
logical pathways. Finally, we implemented SECA: SNP effect con-
cordance analysis using GWAS summary results of toenail and
blood Se levels to examine polygenic risk shared across these
two closely related traits. See Supplementary Methods for details
pertaining to these analyses.
Cross-trait GW meta-analysis
In light of results from our GWAS of toenail Se, which yielded the
same top locus reported for GWAS of blood Se (6), further corrobo-
rated by significant polygenic overlap between the two traits, we
performed a sample-weighted meta-analysis across all GWAS of
toenail and blood Se.We also sought the association between our
top loci and plasma Hcy levels in a previously reported GWAS in
the Women’s Genome Health Study (11).
Expression quantitative trait loci
We examined associations between our top Se SNPs and expres-
sion of nearby genes in whole blood from a recent meta-analysis
of 5300 samples (GEO:GSE36382, GSE20142, GSE20332, GSE33828,
GSE33321, GSE47729; ArrayExpress:E-TABM-1036, E-MTAB-945,
E-MTAB-1708) (9).
Supplementary Material
Supplementary Material is available at HMG online.
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